Thus, we found that current biobank policies vary. The sample of U.S. biobanks that responded to our inquiries was split fairly evenly on whether they even address return of IFs and IRRs. Among those biobanks that do address this issue, some return no findings at all, some return non-genetic IFs (such as abnormal blood pressure) discovered at enrollment, some return a subset of non-genetic or genetic IFs, and some return a subset of non-genetic or genetic IRRs. Table 3 offers examples of biobanks with these different policies.
